Molecular Formula | C20H20ClN5O2 |
Molar Mass | 397.86 |
Appearance | powder |
Color | white to beige |
Storage Condition | 2-8°C |
In vitro study | AS1517499 inhibited Th2 differentiation of mouse spleen T cells induced by IL-4, but had no effect on Th1 differentiation induced by IL-12. AS1517499 was able to prevent the IL-4 activated, stat6-mediated increase in the clonogenic potential of primary PCa cells. At a concentration of 300 nM, AS1517499 reduced the clonal potential of primary basal PCa cells. |
In vivo study | AS1517499 treatment in mice, AS1517499 can inhibit the upregulation of RhoA in tracheal smooth muscle, slow down the antigen induced airway smooth muscle hyperresponsiveness, this may be due to AS1517499 reducing IL-13 production in the mouse trachea. AS1517499 can reduce the preventive effect of apoptotic cell perfusion on bleomycin-induced pulmonary fibrosis by inhibiting PPARγ. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.513 ml | 12.567 ml | 25.135 ml |
5 mM | 0.503 ml | 2.513 ml | 5.027 ml |
10 mM | 0.251 ml | 1.257 ml | 2.513 ml |
5 mM | 0.05 ml | 0.251 ml | 0.503 ml |
biological activity | AS1517499 is a novel potent STAT6 inhibitor with an IC50 of 21 nM. |
Target | TargetValue STAT6 (Cell-free assay) 21 nM |
Target | Value |
STAT6 (Cell-free assay) | 21 nM |
in vitro study | AS1517499 inhibited Th2 differentiation of mouse spleen T cells induced by IL-4, but it had no effect on the differentiation of Th1 induced by IL-12. AS1517499 was able to prevent the IL-4 activated, stat6-mediated increase in the clonogenic potential of primary PCa cells. At a concentration of 300 nM, AS1517499 reduced the clonal potential of primary basal PCa cells. |
in vivo studies | in mice treated with AS1517499, AS1517499 inhibits the upregulation of RhoA in tracheal smooth muscle, the antigen-induced airway smooth muscle hyperreactivity was slowed, possibly due to a IL-13 reduction in the production of mouse trachea by AS1517499. AS1517499 can reduce the preventive effect of apoptotic cell perfusion on bleomycin-induced pulmonary fibrosis by inhibiting PPARγ. |